CSAD

Summary

CSAD (cysteine sulfinic acid decarboxylase, HGNC:18966) is a protein-coding gene on chromosome 12q13.13, encoding Cysteine sulfinic acid decarboxylase (Q9Y600). Catalyzes the decarboxylation of L-aspartate, 3-sulfino-L-alanine (cysteine sulfinic acid), and L-cysteate to beta-alanine, hypotaurine and taurine, respectively.

This gene encodes a member of the group 2 decarboxylase family. A similar protein in rodents plays a role in multiple biological processes as the rate-limiting enzyme in taurine biosynthesis, catalyzing the decarboxylation of cysteinesulfinate to hypotaurine. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 51380 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 104 total
• MANE Select transcript: NM_001244705

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18966
Approved symbol	CSAD
Name	cysteine sulfinic acid decarboxylase
Location	12q13.13
Locus type	gene with protein product
Status	Approved
Aliases	CSADC, PCAP, CSD
Ensembl gene	ENSG00000139631
Ensembl biotype	protein_coding
OMIM	616569
Entrez	51380

Gene structure

Transcript identifiers

Ensembl transcripts: 41 — 31 protein_coding, 5 retained_intron, 3 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000267085, ENST00000379846, ENST00000379850, ENST00000424845, ENST00000424990, ENST00000437073, ENST00000444623, ENST00000453446, ENST00000454442, ENST00000461392, ENST00000472908, ENST00000475890, ENST00000483632, ENST00000485004, ENST00000490589, ENST00000490923, ENST00000491654, ENST00000498635, ENST00000548698, ENST00000885695, ENST00000885696, ENST00000885697, ENST00000885698, ENST00000885699, ENST00000885700, ENST00000885701, ENST00000885702, ENST00000885703, ENST00000943677, ENST00000943678, ENST00000943679, ENST00000943680, ENST00000943681, ENST00000943682, ENST00000943683, ENST00000943684, ENST00000943685, ENST00000943686, ENST00000943687, ENST00000943688, ENST00000943689

RefSeq mRNA: 3 — MANE Select: NM_001244705 NM_001244705, NM_001244706, NM_015989

CCDS: CCDS58235, CCDS8848

Canonical transcript exons

ENST00000444623 — 17 exons

Exon	Start	End
ENSE00001338252	53180732	53180925
ENSE00001785251	53179102	53179142
ENSE00001913209	53157663	53158684
ENSE00003463051	53172346	53172436
ENSE00003495409	53159623	53159712
ENSE00003497571	53161127	53161191
ENSE00003503589	53161273	53161389
ENSE00003516757	53170072	53170126
ENSE00003541373	53160120	53160319
ENSE00003560294	53171882	53171988
ENSE00003570312	53172522	53172648
ENSE00003591127	53160763	53160844
ENSE00003611504	53171326	53171441
ENSE00003652284	53159887	53159938
ENSE00003652892	53173728	53173770
ENSE00003659168	53170423	53170502
ENSE00003675020	53173345	53173476

Expression profiles

Bgee: expression breadth ubiquitous, 263 present calls, max score 98.21.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.4827 / max 235.7852, expressed in 1781 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
131207	5.3508	1415
131208	3.3988	1252
131210	2.2197	800
131205	1.0602	633
131206	1.0321	501
131209	0.2739	84
131204	0.0732	8
131202	0.0537	7
131203	0.0204	8

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	98.21	gold quality
right lobe of liver	UBERON:0001114	97.68	gold quality
mucosa of stomach	UBERON:0001199	97.66	gold quality
left ovary	UBERON:0002119	97.58	gold quality
omental fat pad	UBERON:0010414	97.55	gold quality
right hemisphere of cerebellum	UBERON:0014890	97.52	gold quality
peritoneum	UBERON:0002358	97.50	gold quality
endocervix	UBERON:0000458	97.45	gold quality
right ovary	UBERON:0002118	97.44	gold quality
subcutaneous adipose tissue	UBERON:0002190	97.42	gold quality
cerebellar hemisphere	UBERON:0002245	97.40	gold quality
adipose tissue of abdominal region	UBERON:0007808	97.38	gold quality
cerebellar cortex	UBERON:0002129	97.28	gold quality
peripheral nervous system	UBERON:0000010	97.20	gold quality
nerve	UBERON:0001021	97.20	gold quality
tibial nerve	UBERON:0001323	97.20	gold quality
ectocervix	UBERON:0012249	97.02	gold quality
minor salivary gland	UBERON:0001830	96.71	gold quality
body of pancreas	UBERON:0001150	96.64	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	96.58	gold quality
right lobe of thyroid gland	UBERON:0001119	96.49	gold quality
skin of abdomen	UBERON:0001416	96.48	gold quality
body of uterus	UBERON:0009853	96.48	gold quality
left lobe of thyroid gland	UBERON:0001120	96.38	gold quality
apex of heart	UBERON:0002098	96.37	gold quality
descending thoracic aorta	UBERON:0002345	96.34	gold quality
adenohypophysis	UBERON:0002196	96.30	gold quality
skin of leg	UBERON:0001511	96.24	gold quality
ascending aorta	UBERON:0001496	96.17	gold quality
adipose tissue	UBERON:0001013	96.15	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.24

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

40 targeting CSAD, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-202-5P	99.78	67.65	991
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-7161-5P	99.68	68.92	1592
HSA-MIR-5197-5P	99.64	69.08	1494
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-330-3P	99.41	69.95	2521
HSA-MIR-504-3P	99.30	67.18	1745
HSA-MIR-4505	99.27	67.81	2678

Literature-anchored findings (GeneRIF, showing 2)

• The presence of cysteine inhibited ADC, CSAD and GDC activity. (PMID:22718265)
• taurine biosynthesis in vertebrates involves two structurally related PLP-dependent decarboxylases (cysteine sulfinic acid decarboxylase and glutamic acid decarboxylase like 1) (PMID:26327310)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	csad	ENSDARG00000026348
mus_musculus	Csad	ENSMUSG00000023044
rattus_norvegicus	Csad	ENSRNOG00000011573
drosophila_melanogaster	b	FBGN0000153

Paralogs (7): GAD1 (ENSG00000128683), DDC (ENSG00000132437), GAD2 (ENSG00000136750), HDC (ENSG00000140287), GADL1 (ENSG00000144644), SGPL1 (ENSG00000166224), PDXDC1 (ENSG00000179889)

Protein

Protein identifiers

Cysteine sulfinic acid decarboxylase — Q9Y600 (reviewed: Q9Y600)

Alternative names: Aspartate 1-decarboxylase, Cysteine-sulfinate decarboxylase, Sulfinoalanine decarboxylase

All UniProt accessions (9): Q9Y600, C9JTU8, E9PFW9, F6XLJ2, F8VV11, F8WCW3, H3BQ59, H3BTP4, J3KPG9

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the decarboxylation of L-aspartate, 3-sulfino-L-alanine (cysteine sulfinic acid), and L-cysteate to beta-alanine, hypotaurine and taurine, respectively. The preferred substrate is 3-sulfino-L-alanine. Does not exhibit any decarboxylation activity toward glutamate.

Subunit / interactions. Homodimer.

Tissue specificity. Expressed in liver and brain. Also expressed in both astrocytes and neurons, but lower levels are expressed in astrocytes.

Pathway. Organosulfur biosynthesis; taurine biosynthesis; hypotaurine from L-cysteine: step 2/2.

Similarity. Belongs to the group II decarboxylase family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9Y600-1	1, Long	yes
Q9Y600-2	2, Short
Q9Y600-3	3

RefSeq proteins (3): NP_001231634, NP_001231635, NP_057073 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002129	PyrdxlP-dep_de-COase	Domain
IPR015421	PyrdxlP-dep_Trfase_major	Homologous_superfamily
IPR015424	PyrdxlP-dep_Trfase	Homologous_superfamily

Pfam: PF00282

Enzyme classification (BRENDA):

• EC 4.1.1.29 — sulfinoalanine decarboxylase (BRENDA: 29 organisms, 27 substrates, 36 inhibitors, 24 Km, 5 kcat entries)

Substrate kinetics (BRENDA)

11 substrates with measured Km, best-characterized 11. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
CYSTEINE SULFINATE	0.037–0.94	5
L-CYSTEIC ACID	0.22–4	3
3-SULFINO-L-ALANINE	1.1–1.56	2
CYSTEINE SULFINIC ACIDS	0.18–0.2	2
CYSTEINE SULFONATE	0.536–0.644	2
L-CYSTEINE SULFINATE	1.14–1.16	2
L-CYSTEINE SULFINIC ACID	0.14–2	2
ASP	11	1
CYSTEIC ACID	0.66	1
CYSTEINE SULFINIC ACID	2.07	1
GLU	2.9	1

Catalyzed reactions (Rhea), 3 shown:

• 3-sulfino-L-alanine + H(+) = hypotaurine + CO2 (RHEA:16877)
• L-aspartate + H(+) = beta-alanine + CO2 (RHEA:19497)
• L-cysteate + H(+) = taurine + CO2 (RHEA:25221)

UniProt features (48 total): helix 24, strand 12, turn 4, sequence conflict 4, splice variant 2, chain 1, modified residue 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2JIS	X-RAY DIFFRACTION	1.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y600-F1	96.67	0.97

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 305

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-1614558	Degradation of cysteine and homocysteine

MSigDB gene sets: 192 (showing top): RORA1_01, GOBP_ALPHA_AMINO_ACID_METABOLIC_PROCESS, AREB6_01, FOXO1_01, GOBP_ORGANIC_ACID_BIOSYNTHETIC_PROCESS, FOXD3_01, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, GOBP_SULFUR_COMPOUND_BIOSYNTHETIC_PROCESS, GOBP_SULFUR_COMPOUND_CATABOLIC_PROCESS, YY1_02, KEGG_TAURINE_AND_HYPOTAURINE_METABOLISM, TGCTGAY_UNKNOWN, GOBP_ORGANIC_ACID_CATABOLIC_PROCESS, GOBP_ORGANIC_ACID_METABOLIC_PROCESS, LEE_LIVER_CANCER_DENA_DN

GO Biological Process (4): obsolete L-cysteine catabolic process to hypotaurine (GO:0019449), obsolete taurine biosynthetic process from L-cysteine (GO:0019452), taurine biosynthetic process (GO:0042412), carboxylic acid metabolic process (GO:0019752)

GO Molecular Function (6): aspartate 1-decarboxylase activity (GO:0004068), sulfinoalanine decarboxylase activity (GO:0004782), pyridoxal phosphate binding (GO:0030170), lyase activity (GO:0016829), carbon-carbon lyase activity (GO:0016830), carboxy-lyase activity (GO:0016831)

GO Cellular Component (1): cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Sulfur amino acid metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
carboxy-lyase activity	2
taurine metabolic process	1
alkanesulfonate biosynthetic process	1
oxoacid metabolic process	1
anion binding	1
vitamin B6 binding	1
catalytic activity	1
lyase activity	1
carbon-carbon lyase activity	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2002 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CSAD	CDO1	P78513	826
CSAD	ADO	Q96SZ5	709
CSAD	SLC6A6	P31641	684
CSAD	CTH	P32929	526
CSAD	ARHGEF15	O94989	521
CSAD	BHMT	Q93088	514
CSAD	P0DN79	P0DN79	503
CSAD	H7C2H4	H7C2H4	493
CSAD	NRG2	O14511	457
CSAD	POU6F1	Q14863	450
CSAD	MEOX1	P50221	445
CSAD	SCARF1	Q14162	444
CSAD	MAT1A	Q00266	432
CSAD	SEMA3G	Q9NS98	412
CSAD	MTR	Q99707	399

IntAct

14 interactions, top by confidence:

A	B	Type	Score
CSAD	SH2B1	psi-mi:“MI:0915”(physical association)	0.490
SH2B1	CSAD	psi-mi:“MI:0915”(physical association)	0.490
BMP2K	CSAD	psi-mi:“MI:0915”(physical association)	0.490
CSAD	ANXA1	psi-mi:“MI:0915”(physical association)	0.370
ANXA7	CSAD	psi-mi:“MI:0915”(physical association)	0.370
CDKN1A	CSAD	psi-mi:“MI:0915”(physical association)	0.370
CSAD	GSK3B	psi-mi:“MI:0915”(physical association)	0.370
CSAD	NR1H2	psi-mi:“MI:0915”(physical association)	0.370
CSAD	PIN1	psi-mi:“MI:0915”(physical association)	0.370
RAP1B	CSAD	psi-mi:“MI:0915”(physical association)	0.370
CSAD	RCC1	psi-mi:“MI:0915”(physical association)	0.370
SMN1	CSAD	psi-mi:“MI:0915”(physical association)	0.370
CSAD	TK1	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (19): CSAD (Affinity Capture-RNA), CSAD (Synthetic Growth Defect), CSAD (Two-hybrid), CSAD (Proximity Label-MS), CSAD (Affinity Capture-MS), CSAD (Affinity Capture-MS), CSAD (Positive Genetic), CSAD (Affinity Capture-RNA), CSAD (Affinity Capture-RNA), CSAD (Two-hybrid), CSAD (Two-hybrid), CSAD (Two-hybrid), CSAD (Two-hybrid), CSAD (Two-hybrid), CSAD (Two-hybrid)

ESM2 similar proteins: A0A2H5AIY0, A0A2H5AIY2, A0A2I6B3P0, A0AA51Z3J4, A0PA85, A6QM00, A8XKT0, I1RV23, O88533, O96567, P05031, P14173, P14748, P16453, P17770, P18088, P18486, P20228, P20711, P22781, P27718, P48318, P48319, P48320, P48321, P48861, P54769, P54770, P93082, P93083, Q05329, Q05683, Q06086, Q06087, Q06088, Q0VCA1, Q0ZQX0, Q16S21, Q18953, Q28D99

Diamond homologs: A0A0A2IDH4, A0A2I6B3P0, A0A481NV25, A7B1V0, I0DFJ0, I1RV23, P93082, P93083, Q06085, Q06086, Q06087, Q06088, Q0ZS27, Q2FSD2, Q5E6F9, Q60358, Q6ZJK7, Q9Y600, Q9Z3R1, A0PA85, A2STQ3, A6QM00, E9FCP7, P14748, P18088, P20228, P48318, P48319, P48320, P48321, Q05329, Q05683, Q0VCA1, Q28D99, Q4PRC2, Q5IS68, Q5R7S7, Q64611, Q6ZQY3, Q80WP8

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
CSAD	“down-regulates quantity”	L-aspartate(1-)	“chemical modification”
CSAD	“up-regulates quantity”	“beta-alanine zwitterion”	“chemical modification”

Disease & clinical

Clinical variants and AI predictions

ClinVar

104 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	74
Likely benign	4
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

2757 predictions. Top by Δscore:

Variant	Effect	Δscore
12:53158680:GCCAC:G	acceptor_gain	1.0000
12:53158681:CCAC:C	acceptor_gain	1.0000
12:53158681:CCACC:C	acceptor_gain	1.0000
12:53158682:CAC:C	acceptor_gain	1.0000
12:53158682:CACC:C	acceptor_gain	1.0000
12:53158683:AC:A	acceptor_gain	1.0000
12:53158683:ACCT:A	acceptor_loss	1.0000
12:53158684:CC:C	acceptor_gain	1.0000
12:53158685:C:CA	acceptor_loss	1.0000
12:53158685:C:CC	acceptor_gain	1.0000
12:53158686:T:A	acceptor_loss	1.0000
12:53159687:C:CT	acceptor_gain	1.0000
12:53159688:A:T	acceptor_gain	1.0000
12:53159708:TCAGG:T	acceptor_gain	1.0000
12:53159709:CAGG:C	acceptor_gain	1.0000
12:53159709:CAGGC:C	acceptor_gain	1.0000
12:53159710:AGG:A	acceptor_gain	1.0000
12:53159711:GG:G	acceptor_gain	1.0000
12:53159712:GCTG:G	acceptor_loss	1.0000
12:53159713:C:CC	acceptor_gain	1.0000
12:53159714:T:C	acceptor_loss	1.0000
12:53159722:A:AC	acceptor_gain	1.0000
12:53159881:TCCTA:T	donor_loss	1.0000
12:53159882:CCTA:C	donor_loss	1.0000
12:53159883:CTACC:C	donor_loss	1.0000
12:53159884:TACC:T	donor_loss	1.0000
12:53159939:CTGTG:C	acceptor_loss	1.0000
12:53160115:CCTA:C	donor_loss	1.0000
12:53160116:CTA:C	donor_loss	1.0000
12:53160117:TAC:T	donor_loss	1.0000

AlphaMissense

3204 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:53160275:G:C	F337L	0.998
12:53160275:G:T	F337L	0.998
12:53160277:A:G	F337L	0.998
12:53160276:A:G	F337S	0.996
12:53172348:G:C	S114R	0.996
12:53172348:G:T	S114R	0.996
12:53172350:T:G	S114R	0.996
12:53160244:C:G	D348H	0.995
12:53160276:A:C	F337C	0.994
12:53160277:A:T	F337I	0.994
12:53160828:A:G	W301R	0.994
12:53160828:A:T	W301R	0.994
12:53172423:G:C	F89L	0.994
12:53172423:G:T	F89L	0.994
12:53172425:A:G	F89L	0.994
12:53160277:A:C	F337V	0.993
12:53161370:A:T	V241D	0.993
12:53171950:T:A	E128V	0.993
12:53160190:A:G	W366R	0.992
12:53160190:A:T	W366R	0.992
12:53160220:A:G	C356R	0.992
12:53160243:T:A	D348V	0.992
12:53160279:A:T	L336H	0.992
12:53170497:G:C	H191Q	0.992
12:53170497:G:T	H191Q	0.992
12:53170499:G:C	H191D	0.992
12:53171339:A:G	F185S	0.992
12:53171405:G:T	A163D	0.992
12:53171972:C:G	A121P	0.992
12:53160214:G:T	R358S	0.991

dbSNP variants (sampled 300 via entrez): RS1000085610 (12:53181394 G>A,C), RS1000291424 (12:53157652 T>G), RS1000395353 (12:53163409 C>G,T), RS1000441325 (12:53174795 A>T), RS1000794573 (12:53168663 A>G), RS1000846807 (12:53168392 T>C), RS1001057649 (12:53168299 G>A), RS1001223179 (12:53162786 G>C), RS1001405942 (12:53173941 C>A,T), RS1001457751 (12:53171299 A>G), RS1001508681 (12:53171013 G>A), RS1001716566 (12:53163022 T>C,G), RS1001856855 (12:53179963 G>A,C), RS1001867909 (12:53173234 A>C,T), RS1001960776 (12:53159175 A>C)

Disease associations

OMIM: gene MIM:616569 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001762_263	Obesity-related traits	2.000000e-06
GCST007433_7	Fulminant type 1 diabetes	8.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005000	leptin measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol F	affects cotreatment, decreases methylation, increases expression	2
bisphenol A	decreases expression, affects cotreatment	2
Air Pollutants	increases expression, affects expression, increases abundance	2
Arsenic	decreases expression, increases abundance, affects methylation, affects cotreatment	2
Dexamethasone	increases expression, affects cotreatment, decreases expression	2
Cyclosporine	decreases expression	2
Aflatoxin B1	affects methylation, decreases expression	2
Cadmium Chloride	increases abundance, increases expression	2
Particulate Matter	increases expression, increases abundance	2
aristolochic acid I	increases expression	1
sotorasib	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	increases expression	1
mono-(2-ethylhexyl)phthalate	increases expression	1
sodium arsenite	affects cotreatment, decreases expression, increases abundance	1
perfluorooctanoic acid	increases expression	1
manganese chloride	increases abundance, affects cotreatment, decreases expression	1
entinostat	increases expression	1
candoxin	decreases expression	1
bisphenol B	increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
trametinib	affects cotreatment, increases expression	1
NVP-BKM120	affects cotreatment, increases expression	1
bisphenol AF	increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Vehicle Emissions	increases abundance, increases expression	1
Cadmium	increases abundance, increases expression	1
Cannabidiol	decreases expression	1
Indomethacin	increases expression, affects cotreatment, decreases expression	1
Lead	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1PC	Abcam HeLa CSAD KO	Cancer cell line	Female

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery